MedTrace Logo

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

NCT07505771 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2026-04-06

No results posted yet for this study

Summary

IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.

Conditions

  • Solid Malignancies

Interventions

DRUG

177Lu-IM-3050

177Lu-IM-3050 is a FAP-directed radiopharmaceutical

Sponsors & Collaborators

  • Immunome, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2029-12-31
Completion
2034-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07505771 on ClinicalTrials.gov